Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

Published:2010-10-14 Issue:1 Volume:25 Page:82-88
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Caramazza D,Begna K H,Gangat N,Vaidya R,Siragusa S,Van Dyke D L,Hanson C,Pardanani A,Tefferi A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2010234.pdf

Reference28 articles.

1. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358–367.

2. Pardanani A . JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23–30.

3. Kroger N, Mesa RA . Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008; 22: 474–486.

4. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A . TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008; 22: 1790–1792.

5. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A . CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23: 1441–1445.

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and Predictive Models in Myelofibrosis;Current Hematologic Malignancy Reports;2024-08-24

2. Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis;Annals of Hematology;2023-11-10

3. Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline;British Journal of Haematology;2023-11-06

4. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group;Clinical and Experimental Medicine;2023-09-25

5. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm;Blood Cancer Journal;2023-07-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3